Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study
The utility of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) utility in predicting immune-related adverse events (irAEs) and survival have not been well studied in the context of treatment with immune checkpoint inhibitors (ICIs). We performed a case-control study of ca...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/6/1308 |
id |
doaj-819b9f81de8649f18c8021bf0cf1e270 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Pei Yi Lee Kellynn Qi Xuan Oen Grace Rui Si Lim Juanda Leo Hartono Mark Muthiah Daniel Q. Huang Felicia Su Wei Teo Andrew Yunkai Li Anselm Mak Nisha Suyien Chandran Chris Lixian Tan Peiling Yang E Shyong Tai Kay Wei Ping Ng Joy Vijayan Yee Cheun Chan Li Ling Tan Martin Beng-Huat Lee Horng Ruey Chua Wei Zhen Hong Eng Soo Yap Dawn K. Lim Yew Sen Yuen Yiong Huak Chan Folefac Aminkeng Alvin Seng Cheong Wong Yiqing Huang Sen Hee Tay |
spellingShingle |
Pei Yi Lee Kellynn Qi Xuan Oen Grace Rui Si Lim Juanda Leo Hartono Mark Muthiah Daniel Q. Huang Felicia Su Wei Teo Andrew Yunkai Li Anselm Mak Nisha Suyien Chandran Chris Lixian Tan Peiling Yang E Shyong Tai Kay Wei Ping Ng Joy Vijayan Yee Cheun Chan Li Ling Tan Martin Beng-Huat Lee Horng Ruey Chua Wei Zhen Hong Eng Soo Yap Dawn K. Lim Yew Sen Yuen Yiong Huak Chan Folefac Aminkeng Alvin Seng Cheong Wong Yiqing Huang Sen Hee Tay Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study Cancers neutrophil-to-lymphocyte ratio immunotherapy immune-related adverse events survival |
author_facet |
Pei Yi Lee Kellynn Qi Xuan Oen Grace Rui Si Lim Juanda Leo Hartono Mark Muthiah Daniel Q. Huang Felicia Su Wei Teo Andrew Yunkai Li Anselm Mak Nisha Suyien Chandran Chris Lixian Tan Peiling Yang E Shyong Tai Kay Wei Ping Ng Joy Vijayan Yee Cheun Chan Li Ling Tan Martin Beng-Huat Lee Horng Ruey Chua Wei Zhen Hong Eng Soo Yap Dawn K. Lim Yew Sen Yuen Yiong Huak Chan Folefac Aminkeng Alvin Seng Cheong Wong Yiqing Huang Sen Hee Tay |
author_sort |
Pei Yi Lee |
title |
Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study |
title_short |
Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study |
title_full |
Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study |
title_fullStr |
Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study |
title_full_unstemmed |
Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study |
title_sort |
neutrophil-to-lymphocyte ratio predicts development of immune-related adverse events and outcomes from immune checkpoint blockade: a case-control study |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2021-03-01 |
description |
The utility of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) utility in predicting immune-related adverse events (irAEs) and survival have not been well studied in the context of treatment with immune checkpoint inhibitors (ICIs). We performed a case-control study of cancer patients who received at least one dose of ICI in a tertiary hospital. We examined NLR and PLR in irAE cases and controls. Logistic and Cox regression models were used to identify independent risk factors for irAEs, progression-free survival (PFS), and overall survival (OS). The study included 91 patients with irAEs and 56 controls. Multiple logistic regression showed that NLR < 3 at baseline was associated with higher occurrence of irAEs. Multivariate Cox regression showed that development of irAEs and reduction in NLR from baseline to week 6 were associated with longer PFS. Higher NLR values at baseline and/or week 6 were independently associated with shorter OS. A reduction in NLR from baseline to week 6 was associated with longer OS. In this study of cancer patients treated with ICIs, NLR has a bidirectional relationship with adverse outcomes. Lower NLR was associated with increased occurrence of irAEs while higher NLR values were associated with worse clinical outcomes. |
topic |
neutrophil-to-lymphocyte ratio immunotherapy immune-related adverse events survival |
url |
https://www.mdpi.com/2072-6694/13/6/1308 |
work_keys_str_mv |
AT peiyilee neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT kellynnqixuanoen neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT graceruisilim neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT juandaleohartono neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT markmuthiah neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT danielqhuang neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT feliciasuweiteo neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT andrewyunkaili neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT anselmmak neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT nishasuyienchandran neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT chrislixiantan neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT peilingyang neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT eshyongtai neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT kayweipingng neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT joyvijayan neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT yeecheunchan neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT lilingtan neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT martinbenghuatlee neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT horngrueychua neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT weizhenhong neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT engsooyap neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT dawnklim neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT yewsenyuen neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT yionghuakchan neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT folefacaminkeng neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT alvinsengcheongwong neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT yiqinghuang neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy AT senheetay neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy |
_version_ |
1724220328906850304 |
spelling |
doaj-819b9f81de8649f18c8021bf0cf1e2702021-03-16T00:02:19ZengMDPI AGCancers2072-66942021-03-01131308130810.3390/cancers13061308Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control StudyPei Yi Lee0Kellynn Qi Xuan Oen1Grace Rui Si Lim2Juanda Leo Hartono3Mark Muthiah4Daniel Q. Huang5Felicia Su Wei Teo6Andrew Yunkai Li7Anselm Mak8Nisha Suyien Chandran9Chris Lixian Tan10Peiling Yang11E Shyong Tai12Kay Wei Ping Ng13Joy Vijayan14Yee Cheun Chan15Li Ling Tan16Martin Beng-Huat Lee17Horng Ruey Chua18Wei Zhen Hong19Eng Soo Yap20Dawn K. Lim21Yew Sen Yuen22Yiong Huak Chan23Folefac Aminkeng24Alvin Seng Cheong Wong25Yiqing Huang26Sen Hee Tay27Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeBiostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Haematology-Oncology, National University Cancer Institute, National University Hospital, Singapore 119228, SingaporeDepartment of Haematology-Oncology, National University Cancer Institute, National University Hospital, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeThe utility of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) utility in predicting immune-related adverse events (irAEs) and survival have not been well studied in the context of treatment with immune checkpoint inhibitors (ICIs). We performed a case-control study of cancer patients who received at least one dose of ICI in a tertiary hospital. We examined NLR and PLR in irAE cases and controls. Logistic and Cox regression models were used to identify independent risk factors for irAEs, progression-free survival (PFS), and overall survival (OS). The study included 91 patients with irAEs and 56 controls. Multiple logistic regression showed that NLR < 3 at baseline was associated with higher occurrence of irAEs. Multivariate Cox regression showed that development of irAEs and reduction in NLR from baseline to week 6 were associated with longer PFS. Higher NLR values at baseline and/or week 6 were independently associated with shorter OS. A reduction in NLR from baseline to week 6 was associated with longer OS. In this study of cancer patients treated with ICIs, NLR has a bidirectional relationship with adverse outcomes. Lower NLR was associated with increased occurrence of irAEs while higher NLR values were associated with worse clinical outcomes.https://www.mdpi.com/2072-6694/13/6/1308neutrophil-to-lymphocyte ratioimmunotherapyimmune-related adverse eventssurvival |